Chen D, Varanasi SK, Hara T, et al. CTLA-4 blockade induces CD4 T cell IFNγ-driven microglial phagocytosis and anti-tumor function in glioblastoma. Immunity. 2023. doi:10.1016/j.immuni.2023.07.015.

Williams EA, Brastianos PK, Wakimoto H, et al. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta neuropathologica. 2023. doi:10.1007/s00401-023-02609-6.

Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 2022;604(7906):563-570. doi:10.1038/s41586-022-04585-5.

Tome-Garcia J, Erfani P, Nudelman G, et al. Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma. Nat Commun. 2018;9(1):4020. doi:10.1038/s41467-018-06258-2.

Rahme GJ, Gaskell E, Bernstein BE. GABPβ1L Wakes Up TERT. Cancer Cell. 2018;34(3):358-360. doi:10.1016/j.ccell.2018.08.011.

Godlewski J, Ferrer-Luna R, Rooj AK, et al. MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Reports. 2017;8(6):1497-1505. doi:10.1016/j.stemcr.2017.04.024.

Wang H, Pan J-Q, Luo L, et al. NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer. 2015;14:2. doi:10.1186/1476-4598-14-2.

Miller TE, Liau BB, Wallace LC, et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017;547(7663):355-359. doi:10.1038/nature23000.

Yu D, Khan OF, Suvà ML, et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A. 2017;114(30):E6147-E6156. doi:10.1073/pnas.1701911114.

Chow RD, Guzman CD, Wang G, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci. 2017;20(10):1329-1341. doi:10.1038/nn.4620.